Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Targeting Protein Translation by Rocaglamide and Didesmethylrocaglamide to Treat MPNST and Other Sarcomas.

Chang LS, Oblinger JL, Burns SS, Huang J, Anderson LW, Hollingshead MG, Shen R, Pan L, Agarwal G, Ren Y, Roberts RD, O'Keefe BR, Kinghorn AD, Collins JM.

Mol Cancer Ther. 2020 Mar;19(3):731-741. doi: 10.1158/1535-7163.MCT-19-0809. Epub 2019 Dec 17.

PMID:
31848295
2.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

3.

Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells.

Fuse MA, Plati SK, Burns SS, Dinh CT, Bracho O, Yan D, Mittal R, Shen R, Soulakova JN, Copik AJ, Liu XZ, Telischi FF, Chang LS, Franco MC, Fernandez-Valle C.

Mol Cancer Ther. 2017 Nov;16(11):2387-2398. doi: 10.1158/1535-7163.MCT-17-0417. Epub 2017 Aug 3.

4.

Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.

Oblinger JL, Burns SS, Huang J, Pan L, Ren Y, Shen R, Kinghorn AD, Welling DB, Chang LS.

Exp Neurol. 2018 Jan;299(Pt B):299-307. doi: 10.1016/j.expneurol.2017.06.015. Epub 2017 Jun 10.

5.

Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.

Burns SS, Chang LS.

Methods Mol Biol. 2016;1427:59-72. doi: 10.1007/978-1-4939-3615-1_4.

PMID:
27259921
6.

Components of the eIF4F complex are potential therapeutic targets for malignant peripheral nerve sheath tumors and vestibular schwannomas.

Oblinger JL, Burns SS, Akhmametyeva EM, Huang J, Pan L, Ren Y, Shen R, Miles-Markley B, Moberly AC, Kinghorn AD, Welling DB, Chang LS.

Neuro Oncol. 2016 Sep;18(9):1265-77. doi: 10.1093/neuonc/now032. Epub 2016 Mar 6.

7.

Integration of XNAT/PACS, DICOM, and Research Software for Automated Multi-modal Image Analysis.

Gao Y, Burns SS, Lauzon CB, Fong AE, James TA, Lubar JF, Thatcher RW, Twillie DA, Wirt MD, Zola MA, Logan BW, Anderson AW, Landman BA.

Proc SPIE Int Soc Opt Eng. 2013 Mar 29;8674. doi: 10.1117/12.2007621.

8.

Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.

Spear SA, Burns SS, Oblinger JL, Ren Y, Pan L, Kinghorn AD, Welling DB, Chang LS.

Otol Neurotol. 2013 Oct;34(8):1519-27. doi: 10.1097/MAO.0b013e3182956169.

9.

Simultaneous analysis and quality assurance for diffusion tensor imaging.

Lauzon CB, Asman AJ, Esparza ML, Burns SS, Fan Q, Gao Y, Anderson AW, Davis N, Cutting LE, Landman BA.

PLoS One. 2013 Apr 30;8(4):e61737. doi: 10.1371/journal.pone.0061737. Print 2013.

10.

Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.

Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DB, Chang LS.

Cancer Res. 2013 Jan 15;73(2):792-803. doi: 10.1158/0008-5472.CAN-12-1888. Epub 2012 Nov 14.

11.

Treatment of vestibular schwannoma cells with ErbB inhibitors.

Bush ML, Burns SS, Oblinger J, Davletova S, Chang LS, Welling DB, Jacob A.

Otol Neurotol. 2012 Feb;33(2):244-57. doi: 10.1097/MAO.0b013e31823e287f.

12.

AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.

Bush ML, Oblinger J, Brendel V, Santarelli G, Huang J, Akhmametyeva EM, Burns SS, Wheeler J, Davis J, Yates CW, Chaudhury AR, Kulp S, Chen CS, Chang LS, Welling DB, Jacob A.

Neuro Oncol. 2011 Sep;13(9):983-99. doi: 10.1093/neuonc/nor072. Epub 2011 Jul 21.

13.

Evolution and origin of HRS, a protein interacting with Merlin, the Neurofibromatosis 2 gene product.

Omelyanchuk LV, Pertseva JA, Burns SS, Chang LS.

Gene Regul Syst Bio. 2009 Oct 8;3:143-57.

14.

Spiritual care at the end of life. Hospice uses teamwork to address spiritual and physical needs.

Burns SS.

Health Prog. 1998 May-Jun;79(3):45-6, 49. No abstract available.

PMID:
10180023

Supplemental Content

Loading ...
Support Center